New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2013
11:57 EDTAMAT, RPRX, BSBR, CTICHigh option volume stocks; AMAT RPRX BSBR CTIC
News For AMAT;RPRX;BSBR;CTIC From The Last 14 Days
Check below for free stories on AMAT;RPRX;BSBR;CTIC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
07:58 EDTBSBRFiling reveals Santander Brasil in discussions with Bonsucesso, Reuters says
Subscribe for More Information
July 29, 2014
11:37 EDTRPRXHigh option volume stocks
Subscribe for More Information
10:47 EDTAMATApplied Materials refiles for China approval of Tokyo Electron merger
Subscribe for More Information
July 28, 2014
06:25 EDTAMATApplied Materials implied volatility of 37 at upper end of index mean range
Subscribe for More Information
July 25, 2014
15:36 EDTAMATApplied Materials withdraws merger filing with regulator, DealReporter says
Subscribe for More Information
06:00 EDTAMATApplied Materials implied volatility of 37 at upper end of index mean range
Subscribe for More Information
July 24, 2014
06:02 EDTAMATApplied Materials implied volatility of 38 at upper end of index mean range
July 23, 2014
05:53 EDTAMATStocks with implied volatility movement; IP AMAT
Subscribe for More Information
July 22, 2014
12:53 EDTAMATApplied Materials drops following report of opposition to merger
Subscribe for More Information
12:19 EDTAMATApplied Materials merger report 'pure speculation,' says Stifel
Subscribe for More Information
10:29 EDTAMATApplied Materials weakness a buying opportunity, says ISI Group
Subscribe for More Information
09:47 EDTAMATApplied Materials sees strong opposition to merger in China, DealReporter says
The proposed merger of Applied Materials (AMAT) with Tokyo Electron is facing strong opposition from Chinese regulators, said DealReporter, according to contacts.
July 21, 2014
05:12 EDTCTICCTI BioPharma announces approval of Pixuvri in Israel
CTI BioPharma announced that it has received approval from the Israeli Ministry of Health, or MOH, for Pixuvri. Pixuvri in Israel is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma who have received not more than three previous courses of treatment. The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy. In Israel, Pixuvri will be distributed and marketed by the Neopharm Group, Israel's second largest pharmaceuticals and health products marketer, once Pixuvri is included in the Israeli National Health Basket of drugs by the MOH. Separately, the Dutch Healthcare Authority, or NZa, and the healthcare insurance board College voor zorgverzekeringen, or CVZ, of the Netherlands have approved funding for Pixuvri as an add-on drug for patients who need a third- or fourth-line treatment option for aggressive B-cell lymphoma. This follows the inclusion of Pixuvri on the HOVON, or Haemato Oncology Foundation for Adults in the Netherlands, treatment guidelines, effective June 1. The inclusion on the Dutch list of reimbursed drugs makes Pixuvri the first registered and reimbursed medicine for the treatment of patients with multiply relapsed or refractory aggressive B-cell NHL in the Netherlands.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use